Atopische Dermatitis
Artikelen
Sleep and QOL: the full impact on patients coping with the burden of AD
Understanding the full scope of AD—the unseen burden on patients.
Atopic dermatitis pathophysiology: type 2 inflammation & cytokines
Beneath the skin of patients with AD—type 2 inflammation and the cytokines involved.
Advancing Treatment for Uncontrolled AD and PN: New Approaches
As we continue to advance in our understanding and treatment capabilities, our response to uncontrolled AD and PN becomes more effective, paving the way for a future where patients can lead healthier, more comfortable lives8.
Underneath the Skin: Hidden Challenges of Uncontrolled AD and PN
What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?
Exploring the Unique Characteristics of Atopic Dermatitis (AD) and Prurigo Nodularis (PN)
Explore the distinct clinical manifestations of Atopic Dermatitis (AD) and Prurigo Nodularis (PN), their impact on patients' lives, and the common thread of type 2 inflammation. Understand how these chronic skin conditions differ and intersect in this comprehensive overview.
The Long-Term Impact of Early-Onset Atopic Dermatitis
A recent study led by professor Jonathan Silverberg involving over 30,000 participants has highlighted the significant psychosocial burden faced by adults with early-onset atopic dermatitis (AD). Learn more and continue reading.
Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results
Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.
Opleiding
EADV 2025 with Sanofi: Advanced Dermatology Resources
Discover Sanofi at EADV2025 featuring BioDay registry findings, expert panels, and networking opportunities for dermatology professionals in Paris.
Managing Pediatric Atopic Dermatitis
A DermTalks Podcast – Atopic Dermatitis in Special Populations. This podcast series is dedicated to exploring the management of atopic dermatitis in specific patient groups.
Speaker : Dr. Hannah de Leye, UZ Brussel, Belgium
Managing Atopic Dermatitis During Pregnancy and Breastfeeding
A DermTalks Podcast – Atopic Dermatitis in Special Populations. This podcast series is dedicated to exploring the management of atopic dermatitis in specific patient groups.
Speaker : Dr. Klas Agerberg, Uppsala University Hospital, Sweden
Managing Atopic Dermatitis in Patients with Comorbidities
A DermTalks Podcast – Atopic Dermatitis in Special Populations. This podcast series is dedicated to exploring the management of atopic dermatitis in specific patient groups.
Speaker : Dr. Jon Anders Halvorsen, Oslo, Norway
Managing Atopic Dermatitis in the Elderly
A DermTalks Podcast – Atopic Dermatitis in Special Populations. This podcast series is dedicated to exploring the management of atopic dermatitis in specific patient groups.
Speaker : Dr. Stine Simonsen, Copenhagen University Hospitals, Denmark
Unraveling Biologics: Exclusive Insights from Prof. Christian Vestergaard
We are pleased to share this extract from our recent webinar on ‘New perspectives in the treatment of pediatrics patients with severe Atopic Dermatitis and adult patients with severe prurigo nodularis’ with you. Watch Prof. Christian Vestergaard as he offers a deep dive into Biologics and their Mode of Action pediatric AD.
%20(1).svg)
Bevestig uw status
Bevestig uw status
Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal
speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een ljst met
evenementen en tools en diensten voor uw dagelijkse praktik.